



800 Chesapeake Drive
Redwood City, CA 94063
www.oncomed.com

Paul J. Hastings

Chairman and Chief Executive Officer



Mr. Hastings is the Chairman and CEO of OncoMed Pharmaceuticals. Prior to joining OncoMed in 2006, Mr. Hastings was President and Chief Executive Officer of QLT, Inc. Previous to that, Mr. Hastings served as President and Chief Executive Officer of Alys Pharmaceuticals, which was acquired by Celera Corporation in 2001. From 1999 to 2001, Mr. Hastings served as the President of Chiron BioPharmaceuticals, a division of Chiron Corporation. Prior to that, he was President and Chief Executive Officer of LXR Biotechnology. Mr. Hastings also held a series of management positions of increasing responsibility at Genzyme Corporation, including serving as President of Genzyme Therapeutics Europe as well as President, Genzyme Therapeutics Worldwide. Mr. Hastings also served as Vice President, Marketing and Sales and General Manager, Europe for Synergen, Inc., and previously held a series of marketing and sales management positions with Hoffmann-La Roche.

Mr. Hastings was recently Chairman of the Board of Proteolix (sold to Onyx Pharmaceuticals in 2010), and served on the boards of ViaCell (sold to Perkin-Elmer in 2007). He is currently Lead Director of Pacira Pharmaceuticals and on the board of Relypsa. He also serves as Chairman of the Emerging Companies Section of the Biotechnology Industry Organization, and serves on the board of the Bay Area Biosciences Association (BayBio) and the California Healthcare Institute (CHI).

Mr. Hastings received a Bachelor of Science degree in pharmacy from the University of Rhode Island.